Source-grounded facts extracted from INTENSITY THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2026 results: net income net loss was $2.4 million.
“31, 2025. This increase was partially offset by lower stock-based compensation and one-time expenses related to our reverse stock split in February 2026. Overall, net loss was $2.4 million for the three months ended March 31, 2026, compared to a net loss of $3.3 million for the three months ended March 31, 2025. As of March 31, 2026, cash and cash equivalents”
INTENSITY THERAPEUTICS, INC. reported financial results for the year ended December 31, 2025.
“On March 27, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2025.”
INTENSITY THERAPEUTICS, INC.: Filed amendment to certificate of incorporation to effect a 1-for-25 reverse stock split (effective 2026-02-13).
“On February 13, 2026, Intensity Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-25 (the “Reverse Stock Split”).”
INTENSITY THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 4, 2025, the “Company received a second letter (the “December 2025 Nasdaq Letter”) from Nasdaq stating that the Company is eligible for an additional 180 calendar days, or until June 1, 2026, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Staff of the Nasdaq (the “Staff”) determined that the Company is eligible for the second 180 calendar day period, or until June 1, 2026, to regain compliance with the Rule based on the Staff’s determination that the Company must continue to meet the continued listing requirement”
INTENSITY THERAPEUTICS, INC.: Amended Section 2.7 of Bylaws to reduce stockholder meeting quorum requirement from majority to at least one-third of voting power entitled to vote, effective August 12, 2025 (effective 2025-08-12).
“On August 12, 2025, the Board of Directors of Intensity Therapeutics, Inc. (the “Company”), adopted an amendment (the “Amendment”) to the Amended and Restated Bylaws of the Company (the “Bylaws”). The changes to the Bylaws pursuant to the Amendment are effective as of August 12, 2025. The Amendment amends Section 2.7 of the Bylaws, dealing with a quorum at meetings of stockholders, to generally provide that a quorum is at least one-third of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy. Prior to effectiveness of the Amendment, a quorum is a majority of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy.”
INTENSITY THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“June 6, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “INTS” at this time. In accordance with Nasdaq List”
James Ahlers was removed as other_named_officer at INTENSITY THERAPEUTICS, INC..
“On May 21, 2024, the Board of Directors of Intensity Therapeutics, Inc. (the “Company”) resolved that Mr. James Ahlers (i) shall be removed as an officer of the Company pursuant to the Company’s bylaws”
Thomas I. H. Dubin was appointed as Class I director at INTENSITY THERAPEUTICS, INC..
“appointed Thomas I. H. Dubin to the Board as a Class I director.”
INTENSITY THERAPEUTICS, INC. entered into Collaboration Agreement with The Swiss Group for Cancer Research SAKK valued at funding in the amount of up to approximately $3.0 million (effective 2024-05-06).
“On May 6, 2024, Intensity Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with The Swiss Group for Cancer Research SAKK (“SAKK”).”
INTENSITY THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: net income Net loss was $4.6 million.
“On May 9, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three months ended March 31, 2024.”
INTENSITY THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4), 5605(a)(2), 10A-3).
“April 18, 2024, the Company received a letter (the "Letter") from Nasdaq notifying the Company that, as a result of the resignation of Daniel Donovan from the Audit Committee, the Company is not in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605. The Letter further provides that, pursuant to Nasdaq Listing Rule 5605(c)(4), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605, which cure period will expire the earlier of the Company's next annual stockholders' meeting or April 14, 2025; or if the n”
INTENSITY THERAPEUTICS, INC. reported financial results for year ended December 31, 2023.
“On March 14, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.